Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
2(50%)
Results Posted
200%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_3
3
75%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)

Detailed Status

Active, not recruiting1
Recruiting1
Terminated1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (25.0%)
Phase 33 (75.0%)

Trials by Status

active_not_recruiting125%
recruiting125%
terminated125%
completed125%

Recent Activity

2 active trials
Showing 4 of 4
recruitingphase_2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

NCT05039619
active_not_recruitingphase_3

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

NCT04963296
completedphase_3

Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)

NCT00662818
terminatedphase_3

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

NCT02613910

Clinical Trials (4)

Showing 4 of 4 trials
NCT05039619Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Recruiting
NCT04963296Phase 3

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

Active Not Recruiting
NCT00662818Phase 3

Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)

Completed
NCT02613910Phase 3

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4